The clinical problem begins with anatomy. Left-sided colon cancers, arising in the descending and sigmoid colon where the bowel lumen is narrow and stool is solid, are notorious for presenting as complete obstructions. Unlike tumors on the right side of the colon, where wide lumens and liquid contents delay symptoms, left-sided lesions can seal off the bowel abruptly, causing abdominal distension, vomiting, and the risk of perforation. The traditional response was emergency surgery: remove the obstructed segment, often with a temporary or permanent colostomy, in patients who are frequently dehydrated, septic, and physiologically fragile. Emergency colectomy in this setting carries high rates of complications and stoma creation, and it forecloses the possibility of giving chemotherapy before surgery, a strategy that has shown promise in non-obstructed colon cancer in randomized trials.

Self-expanding metallic stents changed the calculus. Deployed endoscopically across the tumor, a SEMS springs open to hold the narrowed segment patent, restoring bowel transit within hours and converting a surgical emergency into a scheduled operation. Numerous trials and meta-analyses have established stenting as a bridge to surgery as a reasonable alternative to emergency resection, reducing stoma rates and allowing time for optimization. But the technology has long carried an oncological shadow. Manipulating the tumor with a stent could, in theory, dislodge cancer cells and promote dissemination, and some studies have reported increased perineural invasion or local recurrence after stenting. That concern made many oncologists reluctant to extend the stent-to-surgery interval, and guidelines have generally recommended proceeding to surgery within a couple of weeks rather than exploiting the interval for systemic therapy.

The new study, led by Yang Shi, Zhi Wei Zhai, and Ke Cao of Beijing Chaoyang Hospital, Capital Medical University, together with senior authors Zhen Jun Wang and Jia Gang Han, directly confronts that hesitation. Between the two study arms, 105 patients received a stent followed directly by elective surgery, while 141 patients received a stent, then neoadjuvant chemotherapy, then scheduled surgery. All patients had complete obstruction of the left colon caused by cancer. Because patients were not randomized, the investigators used two complementary statistical strategies to level the playing field: one-to-one propensity score matching, which paired patients across arms on baseline characteristics to yield a matched cohort of 206, and an eight-week landmark analysis, which discounts survival time accrued before the chemotherapy arm could realistically have received its treatment, guarding against immortal time bias.

The safety result is the study’s quiet foundation. If adding weeks of chemotherapy while a metal stent sits inside a tumor had caused stents to occlude, migrate, or perforate the bowel, the strategy would be dead on arrival. Instead, SEMS-related complications occurred at nearly identical rates in both groups: 15.5 percent in the neoadjuvant group versus 14.6 percent in the direct-surgery group, a difference that was statistically indistinguishable with a P value of 0.845. In practical terms, the chemotherapy interval did not appear to erode the mechanical integrity of the stent or inflame the tumor-stent interface in ways that endangered patients. That finding addresses the principal fear that has kept the approach out of mainstream practice and gives the survival data room to speak.

And speak they do. In the propensity score-matched cohort, patients who received chemotherapy before surgery had a five-year overall survival of 66.2 percent, compared with 51.7 percent for those who went straight to surgery, a difference highly unlikely to be explained by chance. Disease-free survival, which tracks patients who remain free of any cancer recurrence, diverged even more sharply: 65.3 percent versus 40.0 percent at five years, again with P values below 0.001. The eight-week landmark analysis reproduced the same pattern, confirming that the benefit was not an artifact of comparing patients who survived long enough to receive treatment against those who did not. Kaplan-Meier curves in both the original and matched cohorts separated early and stayed separated, and subgroup analyses of overall survival were consistent across the strata examined.

Multivariable Cox regression, which adjusts simultaneously for multiple prognostic factors, elevated neoadjuvant chemotherapy to the status of an independent protective factor. For overall survival, the hazard ratio was 0.436, with a 95 percent confidence interval of 0.188 to 0.996 and a P value of 0.015, meaning patients receiving the neoadjuvant strategy had less than half the hazard of death over follow-up. For disease-free survival, the hazard ratio was 0.661, with a confidence interval of 0.551 to 0.830 and a P value of 0.002. In the language of clinical epidemiology, these are modest but meaningful effect sizes, and the fact that the chemotherapy variable retained significance after adjustment strengthens the causal interpretation that the treatment itself, rather than some favorable patient characteristic, drove the survival advantage.

The biological logic behind the result is straightforward. Neoadjuvant chemotherapy treats micrometastatic disease while it is most vulnerable, before surgical stress and inflammatory responses can nurture dormant tumor cells, and it can downstage the primary tumor, potentially improving the quality of resection. The FOxTROT international randomized trial, cited by the authors, previously demonstrated that preoperative chemotherapy for operable colon cancer improves pathological outcomes and is well tolerated, but obstructed patients were excluded from such trials precisely because their tumors blocked the way. The stent removes that barrier, literally and figuratively, creating a therapeutic window in which systemic therapy becomes feasible. The present study suggests that window can be exploited safely, with complication rates that do not differ from the direct-surgery pathway.

Important caveats remain. This was a prospective cohort study, not a randomized controlled trial, and even careful propensity matching cannot eliminate every source of confounding; clinicians may have selected fitter patients or less aggressive tumors for the chemotherapy pathway in ways not captured by measured variables. The eight-week landmark analysis mitigates the most dangerous bias, but the authors themselves frame the results as strongly supporting feasibility and oncological safety rather than proving superiority. The study also reflects practice at Chinese tertiary centers with experienced endoscopists, and generalization will depend on reproducing these outcomes elsewhere. Stenting itself carries recognized risks, including perforation and occlusion, and the interplay between specific chemotherapy regimens, such as anti-angiogenic agents, and indwelling stents has raised perforation concerns in earlier literature.

Even so, the direction of travel is clear and the clinical implications are immediate. For the substantial minority of colon cancer patients who present with complete left-sided obstruction, a strategy of stent decompression, neoadjuvant chemotherapy, and elective surgery delivered five-year overall survival approaching two-thirds and disease-free survival of 65 percent, without increasing stent-related complications. If randomized confirmation follows, the standard of care for obstructive left-sided colon cancer could shift from a race to the operating room toward a deliberate, sequenced campaign: reopen the bowel, treat the disease systemically, then resect on planned terms. For patients facing one of the most feared acute presentations of cancer, that sequence could translate into years of additional survival.

Subject of Research: Neoadjuvant chemotherapy after colonic stenting as a bridge to surgery for obstructive left-sided colon cancer

Article Title: Neoadjuvant chemotherapy as a bridge to surgery versus direct surgery following SEMS placement in obstructive left-sided colon cancer: a multicenter prospective cohort study

Article References: Shi, Y., Zhai, Z. W., Cao, K., Ye, C. X., Li, Y. S., Wang, Y. L., Yang, K. Y., Ding, Z., Hu, X. H., Dai, Y., Qian, Q., Wang, G. Y., Wang, Z. J., & Han, J. G. (2026). Neoadjuvant chemotherapy as a bridge to surgery versus direct surgery following SEMS placement in obstructive left-sided colon cancer: a multicenter prospective cohort study. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03623-7

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03623-7

Keywords: colon cancer, colonic obstruction, self-expanding metallic stent, neoadjuvant chemotherapy, bridge to surgery, overall survival, disease-free survival, propensity score matching, British Journal of Cancer, colorectal surgery, oncology, clinical study

The research, led by Zhuo Han and Nan Wang of Tangdu Hospital at the Fourth Military Medical University together with colleagues from Beijing Chaoyang Hospital and Xijing Hospital, analyzed 154 patients with obstructive colorectal cancer treated between 2011 and 2025. Ninety-three patients received a self-expandable metal stent followed by neoadjuvant therapy, while 61 underwent stent placement alone before surgery. Because treatment practices evolved dramatically over the fourteen-year enrollment window, the investigators stratified their analysis into two eras, 2011 to 2020 and 2021 to 2025, to separate the effects of the combined strategy from the effects of technological progress.

The biological rationale behind the combined approach is rooted in the peculiar hostility of the obstructed bowel. Compared with non-obstructive colorectal cancer, obstructed tumors are more often left-sided, larger, more poorly differentiated, and diagnosed at more advanced stages, with a greater tendency toward peritoneal spread. Obstruction also drives a cascade of systemic problems: elevated inflammatory markers such as C-reactive protein and interleukin-6, hypoproteinemia and malnutrition, and reduced physical activity that accelerates muscle loss and frailty. Recent molecular work has even identified distinct features of the obstructed tumor microenvironment, including altered extracellular matrix stiffness, activated cancer-associated fibroblasts, and a dense infiltration of CD8-positive T cells that paradoxically correlates with worse prognosis.

Emergency surgery for these patients carries perioperative mortality rates as high as 10 to 15 percent, along with elevated risks of anastomotic leakage, wound infection, and permanent stoma formation. Self-expandable metal stents, introduced in the 1990s, offered a minimally invasive alternative: an endoscopist deploys a mesh tube across the tumor, restoring bowel continuity within hours and converting an emergency into an elective operation. Meta-analyses have shown lower early complication rates, lower mortality, and far fewer stomas with stenting compared with emergency surgery. Yet long-term oncological concerns persisted, most notably a prospective study reporting significantly higher local recurrence after stenting, possibly linked to microperforations or mechanical manipulation of the tumor releasing circulating tumor DNA.

The new study addresses those concerns by layering neoadjuvant therapy onto the stent pathway. After decompression, multidisciplinary teams at each center assessed patients for systemic treatment based on locally advanced disease, molecular subtype, resectability, and performance status. Regimens ranged from XELOX and FOLFOX chemotherapy to combinations with cetuximab for RAS and BRAF wild-type left-sided tumors, and immunotherapy for patients with microsatellite instability-high or mismatch repair-deficient tumors. The theory is that decompression first reduces bowel wall edema and peritumoral inflammation, creating a healthier substrate for treatment and surgery, while neoadjuvant drugs shrink the tumor, downstage nodal disease, and potentially eradicate micrometastases.

The short-term surgical results were striking. In the 2011 to 2020 cohort, the stent-plus-therapy group had an intraoperative stoma rate of 8.6 percent versus 29.0 percent for stent alone, and postoperative complications of 8.6 percent versus 29.0 percent, both statistically significant differences. These advantages persisted into the 2021 to 2025 period. The authors attribute this to a synergistic mechanism: stent-induced decompression resolves intestinal wall edema and restores blood supply, converting lesions once deemed unsuitable for safe anastomosis into ones where primary reconstruction is feasible, while neoadjuvant therapy further reduces tumor volume and inflammation. Avoiding a stoma carries profound quality-of-life implications, with longitudinal data showing that ostomy patients suffer persistent deficits in physical, emotional, and social functioning for up to a year after surgery.

Pathological outcomes told an equally compelling story about the modern era. In the 2021 to 2025 cohort, 20.7 percent of neoadjuvant-treated patients achieved major tumor regression, graded as Tumor Regression Grade 0 to 1, and rates of T and N downstaging reached 39.7 percent and 60.3 percent respectively, far exceeding the earlier period when regimens consisted mainly of standard chemotherapy alone. The contemporary group also showed significantly fewer positive lymph nodes and significant improvements in pathological T and N stages. The authors link this enhanced response to the evolution of neoadjuvant regimens, including targeted and immune-based combinations that act on both the primary tumor and micrometastatic disease.

Survival analysis revealed a nuanced picture. In the earlier cohort, the neoadjuvant group showed marginally better three- and five-year disease-free and overall survival, but the differences did not reach statistical significance. In the 2021 to 2025 cohort, however, the combined strategy was associated with a statistically significant improvement in overall survival, with a reported P value of 0.013, while disease-free survival had not yet diverged, possibly because follow-up in that cohort remains short at a median of 41.3 months. The authors caution that retrospective design, modest sample size, and the absence of propensity score matching limit causal inference, but the consistency of surgical and pathological benefits across both eras strengthens the overall signal.

Perhaps the most practice-changing finding concerns timing. For patients treated with a stent alone, an interval of 14 to 21 days between stenting and surgery was associated with significantly better overall survival, a window during which decompression restores nutrition, dampens systemic inflammation, and allows prehabilitation without giving the tumor unnecessary time to progress. For patients receiving neoadjuvant therapy, the calculus differs: intervals exceeding 90 days were associated with significantly worse disease-free survival, suggesting that systemic treatment should be completed and surgery performed within roughly three months. A nationwide Chinese survey cited in the paper found that nearly half of stenting hospitals operated within two weeks, while about a fifth waited ten to twelve weeks when neoadjuvant therapy was given, underscoring how variable current practice remains.

The study arrives as two prospective trials, OUTSTAND and NACSOC-02, work to confirm whether stent-based neoadjuvant strategies can be standardized for obstructive left-sided colorectal cancer, with the latter testing immunotherapy combinations after decompression. For now, the retrospective evidence offers a coherent clinical algorithm: decompress with a stent at an experienced center, use the restored physiological window to deliver modern systemic therapy tailored to molecular subtype, and schedule radical surgery within a defined interval, ideally before 90 days elapse. If prospective data validate these findings, the dreaded obstructed bowel, long a surgical emergency defined by rushed decisions and permanent stomas, may instead become the starting point of a carefully sequenced, multidisciplinary treatment plan that improves both survival and the daily lives of patients.

Subject of Research: Neoadjuvant therapy combined with self-expandable metal stent placement for obstructive colorectal cancer

Article Title: Comparative effectiveness of neoadjuvant therapy combined with stent placement versus stent alone in obstructive colorectal cancer: a multicenter retrospective analysis

Article References: Han, Z., Zhang, B., Liu, S., Wu, T., Qiao, Q., He, X., Han, J., & Wang, N. (2026). Comparative effectiveness of neoadjuvant therapy combined with stent placement versus stent alone in obstructive colorectal cancer: a multicenter retrospective analysis. BMC Cancer, 26(1), Article 1139. https://doi.org/10.1186/s12885-026-16728-2

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16728-2

Keywords: colorectal cancer, bowel obstruction, self-expandable metal stent, neoadjuvant therapy, bridge to surgery, overall survival, disease-free survival, tumor regression grade, surgical timing, stoma, immunotherapy, retrospective study